Quarterly Updates15 May 2026, 02:53 pm
Alembic Pharma: FY26 Revenue ₹6,651.38 Cr, PAT ₹608.59 Cr
AI Summary
Alembic Pharmaceuticals Ltd. announced audited financial results for the quarter and financial year ended March 31, 2026. The Board of Directors approved the standalone and consolidated audited financial results. Revenue from operations for FY26 stood at ₹6,651.38 crore, and profit before tax was ₹608.59 crore. The board also recommended a dividend. The audit report issued by KKC & Associates LLP, Chartered Accountants, has an unmodified opinion on the financial results.
Key Highlights
- Alembic Pharma's FY26 revenue from operations reached ₹6,651.38 crore.
- The company's profit before tax for FY26 is ₹608.59 crore.
- Auditors issued an unmodified opinion on the standalone and consolidated audited financial results.
- The Board of Directors approved the audited financial results for FY26 and recommended a dividend.